Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$24.08
-2.2%
$23.11
$13.39
$27.72
$12.29B1.685.15 million shs4.70 million shs
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$18.20
+1.3%
$17.91
$10.41
$25.32
$1.90B0.213.68 million shs3.43 million shs
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-2.28%+0.49%+1.57%+4.18%+66.72%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
+1.28%+9.05%+3.35%-21.65%+2.77%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$24.08
-2.2%
$23.11
$13.39
$27.72
$12.29B1.685.15 million shs4.70 million shs
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$18.20
+1.3%
$17.91
$10.41
$25.32
$1.90B0.213.68 million shs3.43 million shs
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-2.28%+0.49%+1.57%+4.18%+66.72%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
+1.28%+9.05%+3.35%-21.65%+2.77%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.77
Moderate Buy$28.5518.57% Upside
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
2.08
Hold$24.8136.32% Upside

Current Analyst Ratings Breakdown

Latest SRPT and ELAN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/29/2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
DowngradeSell (D+)Sell (D)
6/29/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Reiterated RatingOverweight
6/18/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Boost Price TargetBuy$31.00 ➝ $32.00
6/11/2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
UpgradeSell (D)Sell (D+)
5/26/2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
DowngradeSell (D+)Sell (D)
5/11/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
DowngradeSell (D+)Sell (D)
5/8/2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
UpgradeSell (D)Sell (D+)
5/7/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Boost Price TargetBuy$30.00 ➝ $31.00
5/7/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Boost Price TargetOverweight$28.00 ➝ $30.00
4/27/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
UpgradeSell (D)Sell (D+)
4/22/2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
UpgradeSell (D-)Sell (D)
(Data available from 7/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$4.72B2.55$2.27 per share10.60$13.18 per share1.83
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$2.20B0.87N/AN/A$10.89 per share1.67
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-$232M-$0.50N/A19.731.61-4.95%7.42%3.66%8/6/2026 (Estimated)
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
-$713.41M-$0.96N/A8.790.19-2.94%7.56%2.94%8/5/2026 (Estimated)

Latest SRPT and ELAN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/6/2026Q1 2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.34$0.40+$0.06$0.11$1.28 billion$1.37 billion
5/6/2026Q1 2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$0.9760$3.16+$2.1840$2.88$474.16 million$730.80 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
N/AN/AN/AN/AN/A
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.60
2.16
1.12
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
0.56
4.63
2.62

Institutional Ownership

CompanyInstitutional Ownership
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
97.48%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
86.68%

Insider Ownership

CompanyInsider Ownership
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
1.14%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
6.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
9,400499.45 million493.76 millionOptionable
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
1,372105.58 million98.29 millionOptionable

Recent News About These Companies

SRPT vs. ARGX: Which Stock Is the Better Value Option?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Elanco Animal Health stock logo

Elanco Animal Health NYSE:ELAN

$24.08 -0.54 (-2.17%)
Closing price 07/1/2026 03:59 PM Eastern
Extended Trading
$24.40 +0.32 (+1.35%)
As of 07/1/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Sarepta Therapeutics stock logo

Sarepta Therapeutics NASDAQ:SRPT

$18.20 +0.23 (+1.28%)
Closing price 07/1/2026 04:00 PM Eastern
Extended Trading
$18.23 +0.03 (+0.14%)
As of 07/1/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.